Covenant Partners, LLC Biomarin Pharmaceutical Inc Transaction History

Covenant Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 02, 2021	SELL	$75.51 - $84.79 $230,607 - $258,948	-3,054 Closed	0 $0
Q1 2021 May 11, 2021	BUY	$74.73 - $90.69 $228,225 - $276,967	3,054 New	3,054 $231,000
Q4 2020 Feb 10, 2021	SELL	$72.61 - $90.2 $212,892 - $264,466	-2,932 Closed	0 $0
Q3 2020 Nov 10, 2020	SELL	$71.87 - $131.03 $55,052 - $100,368	-766 Reduced 20.71%	2,932 $223,000
Q2 2020 Aug 17, 2020	BUY	$79.55 - $124.22 $294,175 - $459,365	3,698 New	3,698 $456,000

Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $277,700 - $376,843	-3,891 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $250,074 - $336,065	3,891 New	3,891 $329,000
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $257,400 - $325,035	-3,819 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$80.35 - $93.9 $58,816 - $68,734	732 Added 23.71%	3,819 $327,000
Q1 2019 May 16, 2019	BUY	$84.2 - $98.62 $259,925 - $304,439	3,087 New	3,087 $274,000

623

181M

1.73M

1.73M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Covenant Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Covenant Partners, LLC with notifications on news.